Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies, University of Melbourne Partner on Breast Cancer Risk Test

NEW YORK (GenomeWeb) – Australian molecular diagnostics firm Genetic Technologies announced today that it has partnered with the University of Melbourne to broaden the applicability of its BrevaGenplus breast cancer risk assessment test.

Genetic Technologies' BrevaGenplus is currently designed for women aged 35 years or older who have not had breast cancer but who have one or more risk factors. In collaboration with the University of Melbourne, the company is aiming to expand the test's use to women with an extended family history of the disease, and increase the range of risk factors analyzed by the test.

Additional terms of the deal were not disclosed.

In addition to BrevaGenplus, Genetic Technologies is developing a colorectal cancer risk assessment test. The company also recently partnered with Omix Ventures to develop and access a blockchain-based global genomic data management platform for cancer diagnostic development.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.